Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple key claims conflict with the provided FDA label excerpts: the indication, drug identity/mechanism claim, and efficacy endpoints. Several safety/side-effect assertions are unsupported, and one claim is unrelated to label content (patent exclusivity).
Category Scores
Accurate Statements
Qinlock is a kinase inhibitor.
Supported by Section 12.1 (Mechanism of Action): 'Ripretinib is a tyrosine kinase inhibitor that inhibits KIT... and PDGFRA...'
Unsupported Statements
Qinlock (tanespimycin) is a kinase inhibitor.
Label excerpts describe QINLOCK (ripretinib) and ripretinib mechanism; 'tanespimycin' is not supported by the provided label basis.
In clinical trials, Qinlock showed improved progression-free survival compared to placebo.
The provided label excerpts include study design but do not state progression-free survival results.
In clinical trials, Qinlock showed improved overall survival compared to placebo.
The provided label excerpts include study design but do not state overall survival results.
Common side effects of Qinlock include fatigue.
The provided label excerpts (Sections 5 and 6 shown) list/discuss certain clinically significant adverse reactions but do not support 'fatigue' as a common side effect.
Common side effects of Qinlock include nausea.
Not supported by the provided label excerpts.
Common side effects of Qinlock include diarrhea.
Not supported by the provided label excerpts.
Common side effects of Qinlock include peripheral neuropathy.
Not supported by the provided label excerpts.
Serious side effects of Qinlock can include severe allergic reactions.
Not supported by the provided label excerpts.
Serious side effects of Qinlock can include gastrointestinal perforations.
Not supported by the provided label excerpts.
Serious side effects of Qinlock can include severe diarrhea.
Not supported by the provided label excerpts.
Information on when Qinlock's patent exclusivity expires is not publicly available on DrugPatentWatch.com.
Not a label-supported prescribing-information claim; the provided label excerpt does not address patent exclusivity.
Qinlock is used to treat advanced systemic mastocytosis (SM) with aggression.
The provided label excerpts specify advanced gastrointestinal stromal tumor (GIST), not systemic mastocytosis.
Qinlock is indicated for patients who have tried other treatments and still have evidence of disease.
The provided label excerpt specifies prior treatment with 3 or more kinase inhibitors (including imatinib) for advanced GIST; the 'still have evidence of disease' phrasing is not supported verbatim by the provided label excerpt.
Contradictions
High
AI Statement
Qinlock is used to treat advanced systemic mastocytosis (SM) with aggression.
Label Reference
Section 1 — Indications and Usage: QINLOCK indicated for 'adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.'
High
AI Statement
Qinlock (tanespimycin) is a kinase inhibitor.
Label Reference
Drug/active ingredient in provided label basis: 'QINLOCK (ripretinib)'. Mechanism section refers to 'Ripretinib'.
Important Omissions
No label-supported dosing/administration details were provided in the evaluated response (e.g., 150 mg orally once daily, tablet swallowed whole, missed dose/vomiting guidance).
Importance:
Moderate
No label-supported major warnings/precautions were correctly stated (e.g., palmar-plantar erythrodysesthesia, new primary cutaneous malignancies, hypertension, cardiac dysfunction, impaired wound healing, photosensitivity, embryo-fetal toxicity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Incorrect indication (systemic mastocytosis) is a high-severity labeling mismatch. Multiple adverse reaction claims are unsupported by provided label excerpts, increasing risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Indication and drug identity are inconsistent with the provided FDA label (systemic mastocytosis vs advanced GIST; tanespimycin vs ripretinib). Efficacy and adverse-event claims are mostly unsupported by the provided label excerpts.
Suggested Improvement
Replace the indication with: adult advanced GIST after prior treatment with 3+ kinase inhibitors including imatinib (Section 1). Use ripretinib (QINLOCK) for identity/mechanism (Section 12.1). Remove or qualify unsupported efficacy/side-effect statements unless the provided label text explicitly reports them; instead cite label-supported clinically significant adverse reactions from Sections 5 and 6 and dosing from Section 2.